Less Can Be Enough: Sustained Remission of Pediatric Eosinophilic Esophagitis With Low‐Frequency Dupilumab
Clinical Case Reports · 2026-05 · 14 (5)
DOI: 10.1002/ccr3.72457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Case Reports, online erschienen am 06.05.2026. Verfasst von Giovanni Scatigna und 4 weiteren Autor:innen. Beteiligte Einrichtung: NESMOS Department, Faculty of Medicine and Psychology Sapienza University of Rome, Pediatric Unit, Sant'Andrea University Hospital Rome Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Eosinophilic esophagitis (EoE) is a chronic, immune‐mediated disease requiring long‐term therapy. Dupilumab, an interleukin‐4 and interleukin‐13 receptor antagonist, is approved for EoE at a weekly 300 mg dosing regimen. However, data on reduced‐frequency dosing, especially in pediatric patients, remain limited. This is the case of a 12‐year‐old girl presented with vomiting, food impaction, and dysphagia. Endoscopy revealed longitudinal furrows and whitish exudates (EREFS 4), and histology confirmed EoE with 75 eosinophils/high‐power field (HPF) and high EoEHSS grade and stage scores. Conventional therapies with proton pump inhibitors, topical fluticasone, and an elimination diet achieved only partial improvement. Dupilumab (300 mg every 2 weeks) induced complete clinical, endoscopic (EREFS 0), and histologic remission (EoEHSS grade/stage 0–1, peak < 6 eos/HPF) after 6 months. Given the remission and parental concern about prolonged therapy, the dosing interval was cautiously extended to every 3 weeks as a monitored off‐label trial. Topical steroids and dietary restrictions were discontinued. The patient remained asymptomatic and in complete histologic remission for more than 2 years (as of August 2025: EREFS 0, EoEHSS 0, with a peak eosinophil count of ≤ 6 eos/HPF) without any adverse events. This case illustrates that sustained remission of pediatric EoE may be achievable with individualized, response‐based dupilumab de‐escalation. While promising, this off‐label approach requires confirmation in prospective studies before routine implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NESMOS Department, Faculty of Medicine and Psychology Sapienza University of Rome, Pediatric Unit, Sant'Andrea University Hospital Rome Italy.
ORCID-Profile: Maurizio Mennini
Zitieren
APA
Scatigna, G., Iadecola, A., Piersanti, M., Di Nardo, G., & Mennini, M. (2026). Less Can Be Enough: Sustained Remission of Pediatric Eosinophilic Esophagitis With Low‐Frequency Dupilumab. Clinical Case Reports, 14(5). https://doi.org/10.1002/ccr3.72457
Vancouver
Scatigna G, Iadecola A, Piersanti M, Di Nardo G, Mennini M. Less Can Be Enough: Sustained Remission of Pediatric Eosinophilic Esophagitis With Low‐Frequency Dupilumab. Clinical Case Reports. 2026;14(5). doi:10.1002/ccr3.72457
BibTeX
@article{Scatigna2026,
author = {Scatigna, Giovanni and Iadecola, Annarita and Piersanti, Martina and Di Nardo, Giovanni and Mennini, Maurizio},
title = {Less Can Be Enough: Sustained Remission of Pediatric Eosinophilic Esophagitis With Low‐Frequency Dupilumab},
journal = {Clinical Case Reports},
year = {2026},
volume = {14},
number = {5},
doi = {10.1002/ccr3.72457}
}
EUVIMED